Libtayo (cemiplimab) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Libtayo (cemiplimab) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Libtayo (cemiplimab) is a PD-1 inhibitor used primarily for the treatment of certain types of skin cancers, such as advanced cutaneous squamous cell carcinoma, and has recently been approved for non-small cell lung cancer. Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate specifically designed to target HER2-positive breast cancer and has also shown promise in other HER2-expressing cancers. The choice between Libtayo and Enhertu would largely depend on the type and molecular profile of the cancer being treated, as Libtayo is indicated for cancers with a specific immune environment, while Enhertu is tailored for cancers overexpressing the HER2 protein.
Difference between Libtayo and Enhertu
| Metric | Libtayo (cemiplimab) | Enhertu (fam-trastuzumab deruxtecan-nxki) |
|---|---|---|
| Generic name | Cemiplimab | Fam-trastuzumab deruxtecan-nxki |
| Indications | Cutaneous squamous cell carcinoma, Basal cell carcinoma, Non-small cell lung cancer | HER2-positive breast cancer, HER2-positive gastric cancer |
| Mechanism of action | PD-1/PD-L1 checkpoint inhibitor | HER2-directed antibody and topoisomerase inhibitor conjugate |
| Brand names | Libtayo | Enhertu |
| Administrative route | Intravenous infusion | Intravenous infusion |
| Side effects | Fatigue, rash, diarrhea, musculoskeletal pain | Nausea, fatigue, vomiting, alopecia, constipation |
| Contraindications | Severe hypersensitivity to cemiplimab or its excipients | Severe hypersensitivity to trastuzumab deruxtecan or its excipients |
| Drug class | Monoclonal antibody | Antibody-drug conjugate |
| Manufacturer | Regeneron Pharmaceuticals | Daiichi Sankyo and AstraZeneca |
Efficacy
Libtayo (cemiplimab) for Non-Small Cell Lung Cancer (NSCLC)
Libtayo (cemiplimab) is a fully human monoclonal antibody designed to block the programmed death receptor-1 (PD-1) pathway. It has demonstrated efficacy in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with high levels of PD-L1 expression. In clinical trials, Libtayo has shown a significant improvement in overall survival and progression-free survival in patients with advanced NSCLC compared to chemotherapy. The efficacy of Libtayo is particularly notable in individuals who have not received prior systemic treatment and whose tumors express PD-L1 on at least 50% of their cells.
Libtayo (cemiplimab) in the Treatment Landscape of NSCLC
The use of Libtayo as a first-line treatment for advanced NSCLC has been a significant advancement in the therapeutic landscape. Its efficacy in improving survival outcomes has provided an additional treatment option for patients with high PD-L1 expression, offering a potential alternative to traditional chemotherapy regimens. The benefit of Libtayo is most pronounced in patients without EGFR, ALK, or ROS1 aberrations, where targeted therapies are less effective.
Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Mutant NSCLC
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate that has shown efficacy in the treatment of HER2-mutant non-small cell lung cancer. In clinical studies, Enhertu has achieved impressive response rates in patients with HER2-overexpressing or HER2-mutated NSCLC. The drug has been particularly effective in patients who have previously undergone treatment, including those who have received HER2-targeted therapies, indicating its potential as a valuable treatment option for this subset of lung cancer patients.
Enhertu (fam-trastuzumab deruxtecan-nxki) and its Impact on Treatment Outcomes
The impact of Enhertu on treatment outcomes for patients with HER2-mutant NSCLC is significant, with reported improvements in progression-free survival and overall response rates. Its mechanism of action, which involves the targeted delivery of a cytotoxic payload to HER2-expressing cancer cells, allows for a potent antitumor effect while minimizing exposure to normal cells. This targeted approach has been instrumental in addressing the unmet needs of patients with HER2-mutant NSCLC, providing a new avenue for treatment where limited options were previously available.
Regulatory Agency Approvals
Libtayo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
Enhertu
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Libtayo or Enhertu today
If Libtayo or Enhertu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us